The Metastatic Breast Cancer Preceptorship is a comprehensive programme for Indian practitioners that include scientific presentations, interactive case studies and discussions. This meeting is designed to allow clinicians and young oncologists to stay up-to-date and assimilate new information into daily clinical practice. Spearheaded by an esteemed faculty, the programme provides a platform for clinicians to:
Program Director:Dr D. C. Doval (+91-11-47022252)
Program Coordinator: Dr Chaturbhuj Agrawal (+91-9810354544)
Logistics Coordinator: Mr. Purushottam (+91-9873608440)
Logistics Coordinator: Mr. Manoj Chauhan (+91-9873722247)
| Day 1 : 2nd February, 2019 | |||
| S. No. | Time | Session Topic | Speaker / Facilitator |
| 1 | 17:00-17:20 | Registration | |
| 2 | 17:20-17:30 | Welcome and opening remarks | Dr. D. C. Doval |
| 3 | 17:30-17:50 | The evolving treatment landscape of mBC: The past, present and future | Dr. Vineet Talwar |
| 4 | 17:50-18:10 | Research translation into clinic: Targetable pathways in mBC | Dr. Peush Bajpai |
| 5 | 18:10-18:30 | Tea break | |
| 6 | 18:30-19:30 | Meet the multidisciplinary mBC team at RGCI: How we work together
Facilitator : Dr. Chaturbhuj Agrawal |
Multidisciplinary mBC team Dr. Avinash Rao Dr. Anurag Mehta Dr. Rajeev Kumar Dr. Kumardeep Dutta Dr. Kundan Chufal Dr. Harsha Agarwal |
| 7 | 19:30-19:45 | Ongoing research in the field of breast cancer: RGCI | Dr. D. C. Doval |
| 8 | 19:45-20:00 | Summary of the day and close | Dr. D. C. Doval |
| 9 | 20:00 – onwards | Dinner | |
| Day 2 : 3rd February, 2019 | |||||||||||||||||||
| S. No. | Time | Session topic | Speaker / Facilitator | ||||||||||||||||
| Perspectives in HR+ HER2- mBC | |||||||||||||||||||
| 1 | 9:00-9:10 | Opening remarks | Dr. D. C. Doval | ||||||||||||||||
| 2 | 9:10-9:30 | CDK 4/6 inhibitors in breast cancer: what the existing trials revealed? | Dr. Kumardeep Dutta | ||||||||||||||||
| 3 | 9:30-9:45 | Global real world evidence with Palbociclib: Is it really practice changing? | Dr. Meenu Walia | ||||||||||||||||
| 4 | 9:45-10:00 | Real world evidence with Palbociclib: Experience in Indian patients | Dr. Chaturbhuj Agrawal | ||||||||||||||||
| 5 | 10:00-10:20 | CDK 4/6 inhibitors in breast cancer: what the future looks like | Dr. Chandragouda D. | ||||||||||||||||
| 6 | 10:20-10:40 | Optimal sequencing of available treatment options in the HR+/Her2Neu negative mBC | Dr. P. Suresh | ||||||||||||||||
| 7 | 10:40-11:00 | Panel discussion:The CDK4/6 inhibitors conundrum: How do I choose and which should I use?
Moderator: Dr. Ullas Batra |
Dr. Meenu Walia Dr. Chandragouda D. Dr. Kumardeep Dutta Dr. P. Suresh Dr. Rajat Bajaj Dr. Samit Purohit |
||||||||||||||||
| 8 | 11:00-11:20 | Tea break | |||||||||||||||||
| 9 | 11:20-12:30 | Experience across different mBC patient population: Case Discussion
|
|||||||||||||||||
| Perspectives in metastatic TNBC and HER2+ mBC | |||||||||||||||||||
| 10 | 12:30-12:50 | The role of Molecular Testing in breast cancer: How far we come? | Dr. Moushami Suryavanshi | ||||||||||||||||
| 11 | 12:50-13:10 | Optimizing outcomes in HER2+ mBC: Emerging evidence and practice strategies | Dr. Sameer Khatri | ||||||||||||||||
| 12 | 13:10-13:25 | What progress have we made in metastatic TNBC? | Dr. Sumit Goyal | ||||||||||||||||
| 13 | 13:25-13:45 | Panel discussion : The changing face of TNBC and HER2+ metastatic breast cancer Moderator: Dr. Randeep Singh |
Dr. Sumit Goyal Dr. Pankaj Goyal Dr. Varun Goel Dr. Mansi Sharma Dr. A. P. Dubey Dr. Abhishek Yadav |
||||||||||||||||
| 14 | 13:45-14:00 | Summary and Close | Dr. D. C. Doval | ||||||||||||||||
| 15 | 14:00-Onwards | Lunch and Departure | |||||||||||||||||
RGCIRC, Niti Bagh
